Urology Times staff

“We certainly need to move away from a model of care that is follow up driven by tumor markers or imaging alone,” says Netty Kinsella, RN, MSc, PhD.

“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.

“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

“I think we need to change the mindset that chemotherapy is a bad thing. It is a very good thing when given appropriately and when patients are more likely to get long-term benefit,” says Fred Saad, MD, FRCS.

“The take home message would be that in patients with prior history of kidney stone episodes…receiving 24-hour urine testing prior to starting pharmacologic preventive therapy is associated with a lower probability of a subsequent stone-related event,” says Ryan Hsi, MD, FACS.

“I think this is an extremely exciting space,” says Jai Seth, MD, BSc, MSc, FRCS.

“[The prediction model] worked way better than we expected that it would work,” says Sevag Demirjian, MD.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

“Botox has been a wonderful drug for many, many years,” says Min Dong, MD.

“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

“The take-home message is that it's not a question of if you're going to start doing a hereditary cancer risk assessment, it's when,” says Neal D. Shore, MD, FACS.

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.

“It’s not only about prescribing medications or advising how to use it. It’s about support. It’s about checking how things are going. It’s about motivation when things are primarily not working. It’s about knowledge that things tend to improve with time, and certain functions can just recover independently,” says Marta Skrodzka, MD, PhD.

"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.

“There are, indeed, numerous paths that we are trying to tackle from different angles,” says Gennady Bratslavsky, MD.

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

“We actually found that treatment with percutaneous tibial nerve stimulation was…a safe and very effective way of improving sexual function,” says Varun R. Talanki, MD.

“I think one of the problems is that we do run out of treatments in many of these patients at some point,” says William K. Oh, MD.

“I think this really gave us an advantage to offer better care,” says Shiva J. Maralani, MD.

“I think that it's very clear that this test is independently prognostic,” says Daniel E. Spratt, MD.

“As [nurse specialists], we are uniquely placed in terms of supporting these men through their prostate cancer treatments, and then, obviously, through to their recovery afterwards,” says Netty Kinsella, RN, MSc, PhD.

“The fascinating thing is that we have so many new treatments that are now available to us,” says Leonard G. Gomella, MD, FACS.

“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.

“We have new therapies, both AR-targeted therapies, as well as the use of SBRT, or targeted radiotherapy, that have changed the landscape,” says William K. Oh, MD.

Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, recaps 5 presentations from the 2022 Genitourinary Cancers Symposium.

“The traction on this, I think, is really rather remarkable,” says Neal D. Shore, MD, FACS.